Lack of access to CDK4/6 inhibitors for premenopausal patients with metastatic breast cancer in Brazil: estimation of the number of premature deaths

PURPOSE: A CDK4/6 inhibitor (CDK4/6i) combined with endocrine therapy is the standard of care for patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) metastatic breast cancer (MBC). However, the incorporation of these agents into clinical practice remains challenging. This study...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Ecancermedicalscience
Autori principali: Reinert, Tomás, Pellegrini, Rodrigo, Barrios, Carlos Henrique
Natura: Artigo
Lingua:Inglês
Pubblicazione: Cancer Intelligence 2020
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7434502/
https://ncbi.nlm.nih.gov/pubmed/32863875
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2020.1081
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi